Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Actuate Therapeutics Inc (ACTU)

Actuate Therapeutics Inc (ACTU)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 170,836
  • Shares Outstanding, K 23,243
  • Annual Sales, $ 0 K
  • Annual Income, $ -27,290 K
  • EBIT $ -24 M
  • EBITDA $ -24 M
  • 60-Month Beta -0.34
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 15.58

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.26
  • Number of Estimates 2
  • High Estimate -0.24
  • Low Estimate -0.29
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.61 +31.02%
on 11/20/25
7.79 -5.61%
on 11/28/25
+0.93 (+14.49%)
since 11/04/25
3-Month
5.61 +31.02%
on 11/20/25
8.80 -16.48%
on 09/05/25
-1.37 (-15.71%)
since 09/04/25
52-Week
5.47 +34.37%
on 07/21/25
11.99 -38.70%
on 05/30/25
-1.42 (-16.19%)
since 12/04/24

Most Recent Stories

More News
Actuate Therapeutics Announces Closing of $17.25 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option

CHICAGO and FORT WORTH, Texas, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on...

ACTU : 7.35 (-1.08%)
Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock

CHICAGO and FORT WORTH, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on...

ACTU : 7.35 (-1.08%)
Actuate Therapeutics Announces Proposed Public Offering of Common Stock

CHICAGO and FORT WORTH, Texas, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on...

ACTU : 7.35 (-1.08%)
Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer

Clinical Trial Study to be Conducted at UPMC Hillman Cancer to Evaluate Novel Combination as Frontline Therapy CHICAGO and FORT WORTH, Texas, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics,...

ACTU : 7.35 (-1.08%)
Actuate Therapeutics Advances Clinical Program in Ewing Sarcoma After Positive Phase 1 Trial Demonstrates Complete and Partial Responses in Difficult-to-Treat Pediatric Sarcomas

- Announces Completion of Phase 1 Study of Elraglusib in Pediatric Patients - Prolonged and Durable Complete Responses (CRs) Observed in Two of Ten Refractory Ewing Sarcoma Patients - Two...

ACTU : 7.35 (-1.08%)
Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial

ACTU : 7.35 (-1.08%)
Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO

ACTU : 7.35 (-1.08%)
Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

ACTU : 7.35 (-1.08%)
2 Biopharmaceutical Stocks Focused on Cancer That Wall Street Predicts Will More Than Double

Analysts are uber bullish on Actuate Therapeutics and PDS Biotechnology stocks for the next 12 months. Here’s why.

PDSB : 0.9371 (+4.81%)
ACTU : 7.35 (-1.08%)
BMY : 52.00 (+0.09%)
BNTX : 96.51 (+0.53%)
Actuate Therapeutics Shares Highlights from KOL Event on Positive Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer

ACTU : 7.35 (-1.08%)

Business Summary

Actuate Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers. The company's lead product includes elraglusib. Actuate Therapeutics Inc. is based in FORT WORTH, Texas.

See More

Key Turning Points

3rd Resistance Point 7.76
2nd Resistance Point 7.63
1st Resistance Point 7.49
Last Price 7.35
1st Support Level 7.22
2nd Support Level 7.09
3rd Support Level 6.95

See More

52-Week High 11.99
Fibonacci 61.8% 9.50
Fibonacci 50% 8.73
Fibonacci 38.2% 7.96
Last Price 7.35
52-Week Low 5.47

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar